Bennett H. Myers
MD
Dr. Myers is the Chief Medical Officer of the DENT and Director of the DENT Multiple Sclerosis/Neuro-immunology Center, the DENT Spasticity clinic, and Co-Director of DENT’s Neuromuscular Center. He is an associate Clinical Professor of Neurology at the State University of New York at Buffalo. Dr. Myers’ practice focus includes multiple sclerosis, neuro-immunology, neuromuscular medicine, and botulinum toxin for a range of neurologic disorders.
Dr. Myers is involved in the education of medical students, neurology residents, physician assistants, and nurse practitioners.
Dr. Myers is available to see patients at the MDA/ALS clinic at the Amherst and Orchard Park DENT locations
Research Studies
Dr Myers has over 20 years of clinical research experience, with nearly 10 years experience as a principal investigator.
His experience as a principal investigator includes clinical trials in the following indications; Amyotrophic Lateral Sclerosis (ALS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Huntington’s Disease (HD), Myasthenia Gravis (MG), Multiple Sclerosis (MS), Parkinson’s disease (PD), and upper limb spasticity.
Please see our research page for a list of our currently recruiting and active clinical trials.
Cartesian Aurora
Cartesian Aurora What is the AURORA Study? The aim of the AURORA Study is to assess the safety and effectiveness of an mRNA CAR T-cell therapy, known as Descartes-08, as a potential approach to treat generalized myasthenia gravis. Myasthenia gravis is an autoimmune disease, which means that the immune system mistakenly produces antibodies (proteins that
Novartis “Relieve”
Novartis “Relieve” We are assessing the effectiveness and safety of remibrutinib, an investigational medicine being developed for people who have generalized Myasthenia Gravis (gMG). Click here for More Information Inclusion Criteria: – Have a confirmed, documented diagnosis of gMG: either positive for AChR+ antibody or MuSK+ antibody, or seronegative for both AChR and MuSK antibodies
Sanofi VITALIZE
Sanofi VITALIZE A Phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy. The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will
Generation HD-2
Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study: 25 Years to 50 Years (Adult) Sexes Eligible for Study: All Generation HD-2 Link
SPECIALITIES
- Multiple Sclerosis
- Spasticity
- EMG
- Neuromuscular Disorders
- Peripheral Neuropathies
Board Certifications
- 2003 Neurology
Publications
See publications for Bennett H. Myers, MD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with DENT Neurologic Institute)
Titles
- Director, DENT Multiple Sclerosis Center
- Director, DENT Spasticity Clinic
- Co-Director, DENT Neuromuscular Center
- Associate Clinical Professor of Neurology at the State University of New York at Buffalo
Education
Medical / Graduate Education
SUNY at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY
Internship
Duke University Medical Center, Durham, NC – Internal Medicine
Residency
Duke University Medical Center, Durham, NC – Neurology
Fellowship
Strong Memorial Hospital, Rochester, NY – EMG/Neuromuscular/Myasthenia/MDA
Call us to schedule an appointment
Our entire team, from customer service to patient providers, is focused on the central mission to deliver superior clinical care, advanced neurodiagnostics, clinical research and education that will assist our patients in maximizing their quality of life. We strive to exceed the expectations of our patients, clinical partnerships and community partners.